What is Green Planet Bioengineering Co's earnings per share (EPS)?

Green Planet Bioengineering Co (GPLB) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Green Planet Bioengineering Co Financials

GPLB

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Green Planet Bioengineering Co (GPLB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GPLB FY2025 2026-05-15

Green Planet Bioengineering’s reported pattern is a recurring overhead burn financed by matching small capital infusions, not operating cash generation.

Operating cash burn stayed very close to the net loss across FY2023-FY2025, ending at -$37K versus -$36K in FY2025, while financing inflows repeatedly arrived in similar amounts. That pairing implies the reported losses are mostly cash overhead, so outside funding appears to be covering routine expenses rather than investment-heavy expansion.

The balance-sheet fragments point to no working-capital buffer: FY2025 shows $0 cash, $0 current assets, and $501K of current liabilities. Negative equity also widened from -$349K in FY2021 to -$501K, which means accumulated losses have continued to deepen rather than being offset by retained operating profits.

Some figures from recent filings were inconsistent and were omitted from this summary.

Financial Health Signals

Financial Profile 0/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Green Planet Bioengineering Co's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Liquidity

Green Planet Bioengineering Co's current ratio of 0.00 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Earnings Quality Low Quality

1.02x

For every $1 of reported earnings, Green Planet Bioengineering Co generates $1.02 in operating cash flow (-$37K OCF vs -$36K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$36K

YoY-0.8%

Green Planet Bioengineering Co reported -$36K in net income in fiscal year 2025. This represents a decrease of 0.8% from the prior year.

EPS (Diluted)

$0.00

Green Planet Bioengineering Co earned $0.00 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

Green Planet Bioengineering Co held $0 in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

20M

YoY+0.0%

5Y CAGR+0.0%

10Y CAGR+0.0%

Green Planet Bioengineering Co had 20M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

GPLB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$36K+0.8%	$36K-25.0%	$47K+45.6%	$33K-1.2%	$33K-2.0%	$34K
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$0	$0-100.0%	$300	$0	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$36K-0.8%	-$36K+25.4%	-$48K-46.5%	-$33K+1.2%	-$33K+2.0%	-$34K
EPS (Diluted)	$0.00	$0.00	$0.00	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$11K	N/A	$9K+109.5%	$4K-40.0%	$7K	N/A	$5K-50.1%	$11K
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$150	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	N/A	$0	$0	$0	N/A	$0	$0
Net Income	-$11K	N/A	-$9K-109.5%	-$4K+40.0%	-$7K	N/A	-$5K+50.1%	-$11K
EPS (Diluted)	N/A	N/A	$0.00	$0.00	$0.00	N/A	$0.00	$0.00

GPLB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	N/A	N/A	N/A	N/A	N/A
Current Assets	$0	$0	$0	$0	$0	$0
Cash & Equivalents	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	N/A	N/A	N/A	N/A	N/A
Current Liabilities	$501K+7.7%	$465K+8.3%	$430K+12.5%	$382K+9.3%	$349K+10.4%	$316K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$501K-7.7%	-$465K-8.3%	-$430K-12.5%	-$382K-9.3%	-$349K-10.4%	-$316K
Retained Earnings	-$1.1M-3.3%	-$1.1M-3.4%	-$1.1M-4.7%	-$1.0M-3.3%	-$979K-3.5%	-$946K

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Assets	$0	$0	$0	$0	$0	$0	$0	$0
Cash & Equivalents	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Liabilities	$512K+2.2%	$501K+3.4%	$485K+1.8%	$476K+0.9%	$472K+1.5%	$465K+2.8%	$452K+1.2%	$447K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$512K-2.2%	-$501K-3.4%	-$485K-1.8%	-$476K-0.9%	-$472K-1.5%	-$465K-2.8%	-$452K-1.2%	-$447K
Retained Earnings	-$1.1M-1.0%	-$1.1M-1.5%	-$1.1M-0.8%	-$1.1M-0.4%	-$1.1M-0.6%	-$1.1M-1.2%	-$1.1M0.0%	-$1.1M

GPLB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$37K-4.3%	-$35K+17.9%	-$43K-31.2%	-$33K+1.2%	-$33K+2.6%	-$34K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$35K-17.9%	$43K	$0	N/A	N/A
Financing Cash Flow	$37K+4.3%	$35K-17.9%	$43K+31.2%	$33K-1.2%	$33K-2.6%	$34K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$17K+2.3%	-$17K-159.2%	-$7K-8.9%	-$6K+12.8%	-$7K+38.8%	-$11K-108.1%	-$5K+47.7%	-$10K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0	N/A	$0	$0	$0-100.0%	$35K	$0	$0
Financing Cash Flow	$17K-2.3%	$17K+159.2%	$7K+8.9%	$6K-12.8%	$7K-38.8%	$11K+108.1%	$5K-47.7%	$10K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GPLB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.00
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.00
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$501K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

Is Green Planet Bioengineering Co profitable?

No, Green Planet Bioengineering Co (GPLB) reported a net income of -$36K in fiscal year 2025.

What is Green Planet Bioengineering Co's operating cash flow?

Green Planet Bioengineering Co (GPLB) generated -$37K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

How many shares does Green Planet Bioengineering Co have outstanding?

Green Planet Bioengineering Co (GPLB) had 20M shares outstanding as of fiscal year 2025.

What is Green Planet Bioengineering Co's current ratio?

Green Planet Bioengineering Co (GPLB) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Green Planet Bioengineering Co's cash runway?

Based on fiscal year 2025 data, Green Planet Bioengineering Co (GPLB) had $0 in cash against an annual operating cash burn of $37K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Are Green Planet Bioengineering Co's earnings high quality?

Green Planet Bioengineering Co (GPLB) has an earnings quality ratio of 1.02x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Green Planet Bioengineering Co?

Green Planet Bioengineering Co (GPLB) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.